Modeling the Potential Benefits of Proton Therapy for Patients With Oropharyngeal Head and Neck Cancer

It is critical that rigorous evaluation of technology in radiation oncology be undertaken during the early stages of implementation or when there is a marked cost differential. Prospective clinical data proving the clinical effectiveness of emerging technology may not be available to guide proper investment and development. In these scenarios, models can be used to simulate expected clinical outcomes and predict comparative effectiveness and cost-effectiveness.1 In this edition of the Red Journal, 2 studies use model-based approaches to compare photon intensity modulated radiation therapy (IMRT) to proton beam therapy (PBT) in the treatment of head and neck (H&N) cancers.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research

Related Links:

Publication date: Available online 15 July 2019Source: European Journal of RadiologyAuthor(s): Felix Feldhaus, Georg Böning, Martin Jonczyk, Johannes Kahn, Uli Fehrenbach, M. Maurer, D. Renz, Bernd Hamm, Florian StreitparthAbstractPurposeWe determined whether the Smart MAR metal artifact reduction tool - a three-stage, projection-based, post processing algorithm - improves subjective and objective image quality and diagnostic confidence in patients with dental artifacts and suspected head and neck pathology compared to standard adaptive statistical iterative reconstructions (ASIR V) alone.MethodThe study included 100 ...
Source: European Journal of Radiology - Category: Radiology Source Type: research
AbstractHead and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths in the United States alone. Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals – the anti-PD-1 immune checkpoint inhibitors nivolumab and pembrolizumab – for the treatment of pa...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
ConclusionPatients report satisfactory QOL results after oncologic surgery and reconstruction with preliminary no significant differences in most aspects comparing the two modalities. Therefore, the SCAIF appears as a viable alternative to the gold standard, the RFFF.
Source: European Archives of Oto-Rhino-Laryngology - Category: ENT & OMF Source Type: research
Conclusion: The mandibular rotation tends to have a large influence on dose distribution of the parotid glands for head and neck cancers treated with VMAT.
Source: In Vivo - Category: Research Authors: Tags: Clinical Studies Source Type: research
About 70% of cancers in the oropharynx, which includes the tonsils, soft palate and base of the tongue, are linked to the HPV virus, according to the Centers for Disease Control and Prevention. So it's important to talk to your health care provider about the HPV vaccine, especially if you are 26 years old or [...]
Source: News from Mayo Clinic - Category: Databases & Libraries Source Type: news
Head and neck squamous cell carcinoma (HNSCC) originates from squamous epithelium of the upper aerodigestive tract and is the most common malignancy in the head and neck region. Among HNSCCs, oropharynx squamo...
Source: Journal of Translational Medicine - Category: Research Authors: Tags: Research Source Type: research
Abstract Many tumors including head and neck squamous cell carcinoma (HNSCC) spread along the lymphatic network. Current imaging modalities can only detect sufficiently large metastases. Therefore, adjacent lymph node levels (LNL) are irradiated electively since they may harbor microscopic tumor. We apply Bayesian Networks (BN) to model lymphatic tumor progression. The model can subsequently be used to personalize the risk estimation of microscopic lymph node metastases in newly diagnosed patients based on their distribution of macroscopic metastases. A BN is a graphical representation of a joint probability distr...
Source: Physics in Medicine and Biology - Category: Physics Authors: Tags: Phys Med Biol Source Type: research
Let's get to the punchline because it is a big one: Radiation therapy plus cetuximab led to inferior overall survival (OS) in human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinoma (SCC). It is in light of the recently published results from Radiation Therapy Oncology Group (RTOG) 1016 and De-ESCALaTE HPV that we scope this issue's Oncology Scan to discuss the populist view that has prevailed among the head and neck cancer community for some time now: treatment de-intensification in HPV-positive oropharyngeal SCC (OPSCC).
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Feature Source Type: research
Conclusion: This study identified history of radiation therapy as a significant risk factor for SSI from univariate and multivariate analysis and revealed that patients receiving preoperative professional oral health care at general dental clinics reduce the risk of SSI. Preoperative professional oral health care in cooperation with general dental clinics has been shown to reduce SSI of head and neck free-flap reconstructive surgery.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
In conclusion, HPV-DNA prevalence was significantly lower in our HNSCC patients than worldwide 32–36% estimates (p ≤ 0.001). Although infrequent, oropharyngeal cancer increased over years and showed 21% HPV-DNA positivity, which is close to the worldwide 36–46% estimates (p = 0.16). Besides age, smoking, tumor stage, and treatment, HPV/p16 status was an important determinant of patients’ survival. The HPV and/or p16 positivity patients had a better OS than HPV/p16 double-negative patients (p = 0.05). Thus, HPV/p16 status helps improve prognosis by distinguishing between the more favorab...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Head and Neck Cancer | Intensity-Modulated Radiation Therapy | Oropharyngeal Cancer | Physics | Proton Therapy | Radiation Therapy | Radiology | Study